New investors pump $30m into Cellnovo's mobile diabetes management
This article was originally published in Clinica
Cellnovo, a UK company developing what it claims is the first mobile diabetes management system, has raised £30m ($48.4m) in a series B financing round. The round was led by Edmond de Rothschild Investment Partners, and marks the first UK investment made by French private equity firm. Other participants in the fundraising include new investors Forbion Capital Partners, Auriga Partners, NBGI Ventures and Crédit Agricole Private Equity, as well as Cellnovo's existing shareholders.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.